脑卒中患者采用血栓通胶囊与氯吡格雷的药物经济学对比分析

Comparative analysis of pharmaco-economics between Xueshuantong Capsule and clopidogrel in patients with cerebrovascular accident

目的对脑卒中患者采用血栓通胶囊(CVA)与氯吡格雷的药物经济学进行对比分析。方法选取2019年8月至2020年8月在黑龙江省第二医院就诊的360例脑卒中患者。随机分为对照组和试验组,每组各180例,对照组患者在接受常规脑卒中治疗的同时给予氯吡格雷联合阿司匹林药物治疗,试验组患者给予血栓通胶囊药物治疗,对患者治疗前后记录患者在全部治疗过程中的疗效、不良反应的发生率以及具体的治疗费用,治疗结束后对患者进行定期随访,统计患者的复发情况,治疗结束后对两组患者的治疗过程中药物经济进行分析。结果治疗3个月后两者的疗效比较,差异无统计学意义(P>0.05);试验组3个月及6个月内复发率为1.11%和2.78%,低于对照组的2.22%、3.89%,但差异无统计学意义(P>0.05);两组不良反应发生率分别为8.33%、6.67%,差异无统计学意义(P>0.05);试验组治疗全部费用低于对照组,差异有统计学意义(P<0.05);对照组患者采用氯吡格雷联合阿司匹林的治疗费用明显高于试验组患者采用血栓通胶囊的治疗费用,差异有统计学意义(P<0.05),对于脑卒中患者来说,血栓通胶囊的性价比要高于氯吡格雷联合阿司匹林。结论血栓通胶囊治疗脑卒中具有明显的成本效果优势,可以为治疗脑卒中提供一个较低经济负担的方案。

Objective The pharmacoeconomics of using Xueshuantong Capsule(cerebralvascular accident,CVA)and clopidogrel in stroke patients were compared and analyzed.Methods A total of 360 stroke patients admitted to the Second Hospital of Heilongjiang Province from August 2019 to August 2020 were selected.The patients were randomly divided into the control group and the experimental group,with 180 cases in each group.The patients in the control group were given clopidogrel combined with aspirin while receiving conventional stroke treatment,and the patients in the experimental group were given the drug treatment of Xueshuantong Capsules.Before and after the treatment,the curative effect,the incidence of adverse reactions and the specific treatment costs of the patients in the whole treatment process were recorded.After the treatment,the patients were followed up regularly,and the recurrence of the patients was counted.Pharmacoeconomic analysis.Results The test results showed that there was no significant difference in the efficacy of the two groups after 3 months(P>0.05);the incidence of adverse reactions in the two groups were 8.33%and 6.67%,respectively,and there was no significant difference(P>0.05);the total treatment cost of the experimental group was lower than that of the control group,the difference was There was statistical significance(P<0.05);the treatment cost of clopidogrel combined with aspirin in the control group was significantly higher than the treatment cost of Xueshuantong capsule in the experimental group(P<0.05).The cost performance of Xueshuantong capsule is higher than that of clopidogrel combined with aspirin.Conclusion Xueshuantong capsule has obvious costeffectiveness advantages in the treatment of stroke,and can provide a lower economic burden for the treatment of stroke.